immunogen
efficaci
bpropiolacton
bpl
inactiv
whole
virion
sarscov
wisar
vaccin
evalu
balbc
mice
golden
syrian
hamster
vaccin
prepar
test
without
adjuv
adjuv
system
b
select
test
capac
elicit
high
humor
cellular
immun
respons
wisar
vaccin
evalu
effect
vaccin
dose
adjuv
immunogen
efficaci
mice
effect
vaccin
dose
without
b
adjuv
immunogen
efficaci
hamster
efficaci
evalu
challeng
wildtyp
viru
earli
late
time
point
wk
postvaccin
singl
dose
vaccin
without
adjuv
poorli
immunogen
mice
second
dose
result
signific
boost
antibodi
level
even
absenc
adjuv
use
adjuv
result
higher
antibodi
titer
b
adjuv
vaccin
slightli
immunogen
adjuv
vaccin
two
dose
wisar
without
adjuv
system
highli
efficaci
mice
hamster
two
dose
wisar
without
b
immunogen
two
dose
mg
wisar
without
adjuv
provid
complet
protect
earli
challeng
although
antibodi
titer
declin
group
vaccin
hamster
wk
second
dose
vaccin
hamster
still
partial
protect
wildtyp
viru
challeng
vaccin
adjuv
provid
better
protect
nonadjuv
wisar
vaccin
later
time
point
enhanc
diseas
observ
lung
liver
hamster
follow
sarscov
challeng
regardless
level
serum
neutral
antibodi
ever
acut
respiratori
syndrom
sar
first
recogn
asia
earli
caus
case
death
outbreak
end
juli
caus
agent
newlyidentifi
coronaviru
cov
spread
human
yet
unidentifi
anim
reservoir
civet
cat
possibl
infect
anim
spike
glycoprotein
sarscov
attach
protein
target
protect
neutral
antibodi
respons
sever
sarscov
vaccin
develop
use
differ
vaccin
platform
includ
whole
inactiv
subunit
dna
vector
live
viru
vaccin
immunogen
efficaci
experiment
vaccin
evalu
anim
model
mice
hamster
ferret
nonhuman
primat
evalu
phase
clinic
trial
gener
vaccin
elicit
robust
serum
neutral
antibodi
respons
anim
model
provid
protect
challeng
viru
inclus
aluminum
salt
saponin
adjuv
report
enhanc
immunogen
subunit
inactiv
viru
vaccin
mous
reason
model
screen
candid
sar
vaccin
sarscov
replic
high
titer
respiratori
tract
mice
follow
intranas
inocul
furthermor
mice
develop
neutral
antibodi
respons
confer
protect
subsequ
challeng
howev
young
mice
develop
clinic
ill
pneumon
transient
viru
clear
day
postchalleng
therefor
efficaci
sar
vaccin
judg
quantit
virolog
model
hamster
excel
model
sarscov
infect
vaccin
efficaci
sinc
support
high
level
viral
replic
histopatholog
chang
respiratori
tissu
demonstr
clinic
sign
reduc
activ
follow
intranas
inocul
effici
replic
sarscov
respiratori
tract
follow
intranas
inocul
golden
syrian
hamster
lead
high
viru
titer
lung
day
postinfect
pi
peak
titer
occur
day
pi
pronounc
pneumon
accompani
sarscov
infect
day
pi
consolid
onethird
lung
occur
day
pi
viral
replic
pulmonari
patholog
coincid
greatli
reduc
physic
activ
hamster
thu
efficaci
sar
vaccin
judg
quantit
virolog
histopatholog
chang
lung
hamster
studi
evalu
immunogen
efficaci
bpropiolacton
bpl
inactiv
whole
virion
sarscov
vaccin
balbc
mice
golden
syrian
hamster
specif
examin
three
variabl
respons
differ
dose
antigen
effect
differ
adjuv
durat
protect
evalu
administ
challeng
viru
vaccin
hamster
wk
postvaccin
virus
cell
sarscov
urbani
strain
obtain
center
diseas
control
prevent
atlanta
ga
viru
stock
produc
vero
cell
obtain
atcc
serumfre
condit
use
optipro
medium
invitrogen
paisley
scotland
vaccin
prepar
vero
cell
grown
serumfre
condit
infect
dilut
v
v
sarscov
viru
stock
ml
optipro
medium
per
tray
cell
nunc
roskild
denmark
cell
incub
h
day
pi
cytopath
effect
cpe
visibl
viru
harvest
collect
cell
supernat
infecti
titer
viru
determin
use
cell
cultur
infecti
dose
ccid
method
vaccin
purif
perform
lowspe
centrifug
clarifi
cell
harvest
sarscov
chemic
inactiv
bpl
v
v
incub
h
follow
second
incub
h
room
temperatur
hydrolyz
residu
bpl
viru
inactiv
document
titrat
sampl
inactiv
well
complet
purif
concentr
vaccin
follow
bpl
inactiv
polyethylen
glycolsodium
chlorid
pegnacl
mixtur
ad
precipit
inactiv
viru
centrifug
viru
pellet
resuspend
nacltrisedta
nte
buffer
ph
load
onto
sucros
gradient
viru
prepar
ultracentrifug
select
sucros
gradient
fraction
collect
purif
sarscov
recov
sucros
w
v
mm
nacl
mm
tri
mm
edta
ph
addit
bpl
v
v
final
ad
pool
bacteriostat
agent
total
protein
content
determin
lowri
method
mgml
rel
concentr
protein
determin
densitometri
scan
coomassiestain
silverstain
sdspage
gel
vaccin
formul
singledos
vial
wisar
contain
equival
either
mg
protein
final
formul
prepar
shortli
vaccin
addit
ml
pb
ml
adjuv
glaxosmithklin
biolog
rixensart
belgium
ml
wisar
prepar
contain
approxim
sar
protein
adjuv
system
b
contain
mg
lipid
mpl
mg
highli
purifi
saponin
quillaja
saponaria
molina
ml
liposom
adjuv
system
oilinwaterbas
emuls
oil
phase
contain
dlatocopherol
squalen
aqueou
phase
contain
nonion
deterg
polysorb
tween
inactiv
viru
infect
follow
bpl
treatment
confirm
assay
infect
sampl
vero
cell
cpe
observ
two
passag
addit
quantit
pcr
qpcr
perform
sever
time
point
passag
confirm
absenc
amplif
viru
genom
concentr
viral
protein
determin
mgml
total
protein
concentr
concentr
vero
host
cell
protein
hcp
final
materi
determin
elisa
western
blot
analysi
use
serial
dilut
vero
hcpcontain
lysat
found
total
protein
concentr
sampl
group
mice
immun
intramuscularli
im
day
wisar
dose
mg
mg
mg
sar
sprotein
absenc
adjuv
addit
either
b
adjuv
group
mice
infect
intranas
tcid
sarscov
volum
ml
serv
posit
control
sarscov
lethal
young
balbc
mice
viru
replic
respiratori
tract
mice
clear
day
pi
group
mice
immun
im
pb
bplinactiv
influenza
viru
mg
total
hemagglutinin
protein
prepar
vero
cell
administ
without
adjuv
b
includ
neg
control
sera
collect
determin
sarscovspecif
neutral
antibodi
titer
prior
first
immun
preble
second
immun
challeng
schedul
murin
immun
challeng
collect
sampl
shown
fig
three
week
second
dose
vaccin
mice
lightli
anesthet
challeng
tcid
sarscov
two
day
later
mice
euthan
lung
collect
process
determin
viru
titer
group
femal
golden
syrian
hamster
immun
im
day
wisar
use
dose
mg
mg
sar
sprotein
mg
total
protein
absenc
adjuv
addit
b
adjuv
adjuv
includ
hamster
studi
mous
experi
reveal
higher
antibodi
respons
b
addit
control
group
hamster
infect
sarscov
tcid
hamster
immun
im
b
adjuv
flubpl
mg
total
protein
per
dose
sera
collect
determin
sarscovspecif
neutral
antibodi
titer
prior
first
immun
hamster
preble
prior
second
immun
prior
challeng
order
measur
efficaci
vaccin
earli
late
challeng
group
hamster
subdivid
two
group
n
one
earli
challeng
late
challeng
wk
follow
second
immun
respect
challeng
infect
hamster
lightli
anesthet
inocul
tcid
sarscov
ml
two
day
challeng
peak
viru
titer
anticip
lung
sarscovinfect
hamster
hamster
group
euthan
lung
collect
process
quantit
virolog
anoth
group
hamster
sacrif
histopatholog
examin
day
follow
challeng
pulmonari
consolid
occur
sarscovinfect
hamster
select
lung
section
stain
sarscov
antigen
immunohistochemistri
schedul
hamster
immun
challeng
collect
sampl
shown
fig
twofold
dilut
heatinactiv
serum
test
microneutr
assay
use
tcid
sarscov
previous
describ
presenc
viral
cytopath
effect
read
day
tcell
respons
measur
ic
determin
use
adapt
method
describ
suni
et
al
pbmc
sampl
obtain
postimmun
stimul
vitro
mgml
wisar
h
cultur
overnight
presenc
brefeldin
mgml
cell
stain
convent
method
analyz
flow
cytometri
measur
frequenc
ifnsecret
cell
tcell
respons
limit
detect
experi
singl
dose
wisar
vaccin
poorli
immunogen
low
titer
serum
neutral
antibodi
respons
detect
mice
receiv
either
intermediateor
highdos
wisar
vaccin
contain
equival
mg
sprotein
fig
second
dose
vaccin
induc
signific
boost
neutral
antibodi
titer
dose
level
without
adjuv
fig
antibodi
respons
mice
receiv
wisar
b
greater
seen
mice
receiv
wisar
significantli
greater
seen
mice
receiv
wisar
vaccin
alon
dose
p
fig
vaccin
anim
higher
serum
neutral
antibodi
titer
mice
recov
infect
tcid
sarscov
although
studi
previou
studi
mice
hamster
shown
low
level
neutral
antibodi
suffici
prevent
detect
viral
replic
follow
challeng
tcell
respons
sarscov
detect
pbmc
group
although
spleen
collect
experi
sarsspecif
cell
previous
detect
spleen
mice
immun
b
adjuv
wisar
vaccin
higher
cellular
respons
observ
b
adjuv
data
shown
mice
receiv
adjuv
wisar
develop
detect
tcell
respons
tcell
respons
significantli
higher
adjuv
wisar
vaccin
wisar
vaccin
without
adjuv
dose
mg
sprotein
p
fig
trend
toward
higher
cellular
immun
respons
observ
b
adjuv
p
optim
wisar
antigen
dose
mg
fig
wisar
vaccin
highli
efficaci
mice
dosag
level
without
adjuv
challeng
viru
replic
titer
tcid
g
lung
mice
receiv
flubpl
without
adjuv
pb
mean
viru
titer
lung
mice
recov
prior
infect
sarscov
tcid
g
correspond
reduct
titer
compar
mice
receiv
pb
influenza
vaccin
replic
challeng
viru
detect
lung
mice
receiv
wisar
alon
wisar
b
fig
adjuv
includ
hamster
studi
higher
antibodi
respons
seen
b
adjuv
mous
studi
three
week
follow
singl
dose
vaccin
hamster
receiv
mg
wisar
b
higher
serum
neutral
antibodi
respons
group
receiv
wisar
alon
mg
wisar
b
adjuv
howev
neutral
antibodi
titer
modest
lower
respons
seen
hamster
recov
prior
infect
sarscov
fig
administr
second
dose
vaccin
induc
signific
boost
serum
neutral
antibodi
titer
group
group
receiv
mg
wisar
b
antibodi
titer
equival
hamster
recov
prior
infect
sarscov
fig
lower
dose
wisar
mg
sprotein
without
adjuv
hamster
seroconvert
wk
postimmun
presenc
b
adjuv
hamster
detect
sarscovspecif
serum
neutral
antibodi
respons
fourfold
higher
vaccin
dose
wisar
mg
sprotein
without
adjuv
hamster
seroconvert
follow
singl
dose
vaccin
presenc
adjuv
b
hamster
seroconvert
singl
dose
variabl
antibodi
respons
among
ageand
gendermatch
hamster
like
reflect
fact
outbr
follow
second
immun
hamster
seroconvert
sarscov
except
two
anim
ceiv
wisar
mg
sprotein
absenc
adjuv
although
inclus
b
enhanc
antibodi
level
antibodi
level
hamster
receiv
two
dose
vaccin
still
reach
seen
mice
follow
dose
vaccin
sera
collect
wk
wk
follow
second
dose
vaccin
prior
earli
late
challeng
test
togeth
declin
titer
note
vaccin
group
wk
postimmun
titer
stabl
control
group
hamster
infect
sarscov
fig
absenc
adjuv
dosedepend
respons
seen
wisar
vaccin
hamster
antibodi
titer
group
hamster
receiv
low
dose
mg
sprotein
equival
wisar
vaccin
without
adjuv
limit
detect
mean
serum
neutral
antibodi
titer
higher
hamster
receiv
mg
sprotein
hamster
receiv
mg
sprotein
two
dose
vaccin
either
wisar
alon
contain
mg
equival
sprotein
wisar
b
mg
sprotein
equival
provid
complet
protect
pulmonari
replic
viru
upon
challeng
wk
vaccin
earli
challeng
fig
hamster
challeng
wk
second
dose
vaccin
none
vaccin
hamster
fulli
protect
replic
challeng
viru
howev
viru
titer
anim
receiv
adjuv
vaccin
lower
seen
anim
receiv
nonadjuv
vaccin
titer
anim
lower
seen
hamster
control
group
receiv
flubpl
b
vaccin
hamster
recov
sarscov
infect
still
fulli
protect
replic
challeng
viru
wk
infect
histopatholog
find
vari
within
group
among
tissu
collect
earli
late
challeng
repres
photomicrograph
late
challeng
anim
shown
fig
addit
reduct
viral
titer
detect
lung
histopatholog
find
lung
immun
hamster
indic
wisar
vaccin
without
adjuv
confer
protect
homolog
sarscov
challeng
three
flubplvaccin
control
anim
lack
detect
level
sarscov
neutral
antibodi
one
hamster
immun
wisar
mg
sprotein
absenc
adjuv
anim
sever
lung
lesion
includ
perivascular
lymphocyt
cuff
bronchiolar
lesion
vascul
subendotheli
infiltr
interstiti
alveolar
lesion
robert
et
al
includ
adenomat
lesion
peribronchiolar
alveolar
epitheli
prolif
lesion
fig
b
hamster
detect
level
serum
neutral
antibodi
sarscov
time
challeng
protect
sever
lung
lesion
fig
hamster
vaccin
sprotein
alon
adjuv
patholog
lesion
fig
hamster
previous
infect
sarscov
mild
focal
lung
lesion
alveolar
bronchiol
fig
without
viral
antigen
ihc
fig
histopatholog
liver
limit
occasion
small
foci
lymphoid
inflamm
found
group
n
per
group
except
previous
sarscovinfect
recov
group
appar
exacerb
diseas
observ
group
direct
correl
sarscov
neutral
antibodi
presenc
liver
foci
appar
data
shown
vaccin
base
whole
inactiv
virus
advantag
vaccin
approach
comparison
vaccin
influenza
viru
two
differ
mous
strain
whole
inactiv
viru
vaccin
produc
higher
neutral
hemagglutin
inhibit
antibodi
titer
either
virosom
subunit
vaccin
present
stabil
antigen
target
viral
neutral
whole
inactiv
vaccin
mimic
wildtyp
viru
better
subunit
virosom
vaccin
may
account
greater
immunogen
wholevirion
vaccin
furthermor
whole
inactiv
vaccin
present
complex
antigen
target
neutral
subunit
vaccin
abl
reproduc
conform
interact
hepat
viru
although
antibodi
rais
sarscov
sprotein
suffici
viru
neutral
whole
inactiv
vaccin
present
sprotein
trimer
conform
mimick
wildtyp
viru
addit
whole
inactiv
vaccin
also
cost
effect
easili
gener
recombin
vector
vaccin
inactiv
vaccin
use
studi
prepar
propag
sarscov
urbani
strain
vero
cell
subsequ
inactiv
bpl
use
method
easili
scale
bpl
select
inactiv
agent
break
structur
nucleic
acid
reaction
purin
base
wide
use
inactiv
dna
rna
virus
see
et
al
found
bplinactiv
sarscov
vaccin
adjuv
alum
gener
higher
titer
neutral
antibodi
protect
mice
recombin
adenoviru
vaccin
express
n
protein
multipl
viru
inactiv
approach
uv
irradi
formalin
bpl
treatment
use
prepar
whole
virusinactiv
vaccin
interestingli
sarscov
virion
inactiv
uv
irradi
addit
formalin
treatment
skew
cellular
immun
respons
toward
type
possibl
carbonyl
group
gener
formalin
recent
describ
moghaddam
et
al
tsunetsuguyokota
et
al
vero
cell
certifi
cell
line
current
use
product
regist
polioviru
rotaviru
vaccin
high
infecti
titer
virion
yield
obtain
prepar
sarscov
vaccin
featur
present
attract
basi
industri
develop
sever
studi
demonstr
feasibl
differ
vaccin
approach
sar
result
mani
studi
indic
neutral
antibodi
respons
sprotein
import
correl
immun
sar
preclin
model
magnitud
antibodi
respons
significantli
increas
adjuv
recent
studi
employ
new
gener
adjuv
develop
glaxosmithklin
biolog
clearli
demonstr
superior
adjuv
system
alum
nonadjuv
vaccin
eg
hpv
vlp
adjuv
addit
recombin
circumsporozoit
proteinbas
vaccin
rt
adjuv
b
season
pandem
split
influenza
vaccin
adjuv
robust
term
dosespar
breadth
crossprotect
induct
longterm
immun
present
work
establish
benefit
use
new
gener
proprietari
glaxosmithklin
biolog
adjuv
system
improv
efficaci
sar
cov
adjuv
system
b
contain
two
potent
immunostimul
mpl
lipid
highlypurifi
saponin
extract
bark
south
american
tree
quillaja
saponaria
molina
extens
evalu
anim
model
clinic
trial
activ
tolllik
receptor
mpl
act
innat
immun
respons
also
induct
humor
cellular
immun
respons
addit
also
shown
improv
humor
cellmedi
immun
preclin
clinic
trial
notabl
anim
vaccin
vaccin
includ
b
adjuv
develop
measur
tcell
respons
pbmc
nevertheless
previou
experi
tcell
respons
detect
spleen
anim
immun
adjuv
vaccin
respons
could
play
role
protect
sar
cov
although
consid
potent
adjuv
antibodi
respons
oilinwaterbas
adjuv
shown
induc
local
inflamm
attract
immunocompet
cell
inject
site
furthermor
plantderiv
liposolubl
vitamin
e
dlatocopherol
includ
adjuv
system
increas
antibodi
titer
enhanc
product
cytokin
lead
greater
prolifer
cell
reduc
product
prostaglandin
pge
tcellsuppress
factor
characterist
adjuv
could
explain
rel
high
cellular
immun
respons
observ
mice
immun
adjuv
context
lerouxroel
et
al
found
cell
cell
import
control
diseas
pathogenesi
sar
replic
primari
sarscov
infect
senesc
mice
robert
et
al
model
deplet
cell
result
enhanc
immunemedi
interstiti
pneumon
delay
clearanc
sarscov
lung
associ
reduc
neutral
antibodi
cytokin
product
reduc
pulmonari
recruit
lymphocyt
base
promis
data
studi
mice
wisar
vaccin
evalu
golden
syrian
hamster
model
efficaci
measur
quantit
virolog
well
pulmonari
patholog
follow
challeng
bplinactiv
wisar
vaccin
immunogen
efficaci
hamster
gener
observ
consist
studi
sar
vaccin
vaccin
elicit
robust
serum
neutral
antibodi
respons
anim
model
provid
protect
challeng
viru
though
system
antibodi
may
confer
steril
immun
model
mucos
immun
may
enhanc
level
protect
studi
also
demonstr
addit
correl
reduc
histolog
evid
lung
diseas
vaccin
hamster
furthermor
even
low
neutral
antibodi
titer
log
evid
protect
reduct
viru
titer
reduc
histopatholog
recommend
also
evalu
efficaci
wisar
vaccin
earli
late
time
point
assess
durat
protect
hamster
studi
vaccineinduc
protect
last
month
hamster
protect
replic
challeng
viru
robust
time
presenc
b
adjuv
absenc
twoway
anova
p
compar
noadjuv
b
adjuv
vaccin
group
examin
lung
liver
evid
f
lack
viral
antigen
seen
mild
lung
lesion
hamster
previous
infect
sarscov
hematoxylin
color
imag
avail
onlin
wwwliebertonlinecomvim
enhanc
diseas
hamster
follow
challeng
base
report
hepat
diseas
follow
challeng
ferret
immun
modifi
vaccinia
viru
express
sar
sprotein
even
absenc
detect
serum
neutral
antibodi
enhanc
diseas
observ
follow
sarscov
challeng
data
present
articl
reveal
nonadjuv
wisar
vaccin
immunogen
provid
high
level
protect
earli
challeng
mice
hamster
protect
correl
presenc
high
serum
neutral
antibodi
titer
anim
howev
declin
antibodi
titer
observ
hamster
wk
declin
less
pronounc
anim
immun
adjuv
vaccin
better
robust
protect
late
challeng
seen
anim
immun
adjuv
wisar
vaccin
anim
immun
nonadjuv
wisar
vaccin
data
confirm
absenc
histopatholog
find
lung
anim
addit
data
indic
adjuvant
wisar
vaccin
import
antigen
spare
demonstr
advantag
includ
adjuv
achiev
highli
protect
sustain
immun
respons
maintain
accept
level
safeti
vaccin
use
adjuv
potenti
immunogen
wisar
prepar
result
measur
lung
patholog
safeti
concern
vaccin
anim
declin
efficaci
vaccin
measur
wk
late
challeng
compar
earli
wk
challeng
coincid
declin
neutral
antibodi
respons
seen
time
interestingli
declin
protect
efficaci
upon
late
challeng
seen
hamster
initi
infect
live
sarscov
sinc
anim
similar
neutral
antibodi
titer
time
challeng
rel
vaccin
anim
possibl
compon
adapt
immun
respons
involv
sustain
robust
protect
